CTLA4 and lymphoma: CTLA-4 inhibitors, DNA methyltransferase inhibitors, chimeric antigen receptor T-cell therapy are also being explored in relapsed/refractory lymphomas, and there is hope for future use in extranodal lymphomas as well [389].